Vaccine Testing and mRNA/RNA Therapies
Support your vaccine development with in vivo immunogenicity testing, biodistribution studies, and in vitro immunoassays
InnoSer’s Vaccine Testing Services and Study Types
As a preclinical contract research organization (CRO), InnoSer supports your vaccine development with in vivo immunogenicity testing, biodistribution studies, and in vitro immunoassays (cell-based assays, cytotoxicity). Different approaches can enhance the stability, safety, and efficiency of mRNA/RNA therapies.
InnoSer’s immunology experts offer customized study designs to determine vaccine safety and efficacy profiles. Optimization of delivery methods is crucial, as mRNA’s instability and negative charge require suitable carriers for in vivo delivery. Our team has a track record in supporting lipid nanoparticle and other delivery methods to improve mRNA vaccine safety and efficiency.
✓ Immunogenicity studies.
✓ Dose optimization studies.
✓ Local and systemic tolerance assessment.
✓ Pharmacokinetics and Pharmacodynamics (PK/PD) studies.
✓ Biodistribution studies.
✓ Vaccine efficacy studies in disease models.
✓ Complementary in vitro immunoassays with cell lines or primary immune cell populations.
As a preclinical immunology CRO, InnoSer partners with you to navigate this complexity, focusing on innovative approaches, including LNPs for gene therapy. Nanoparticle-mediated delivery systems enhance mRNA vaccine stability, biocompatibility, and targeting, protecting mRNA molecules from degradation and improving delivery to target cells and tissues, including the brain.
With flexible, fast study start times, you can accelerate your research. Outsourcing your preclinical vaccine and mRNA therapy studies to InnoSer gives you access to our comprehensive in vitro and in vivo immunology drug development portfolio, enhancing the precision and effectiveness of your therapeutic candidates.
Vaccine Testing Sample Data
Results following immunogenicity and tolerability study comparing different mRNA-LNP vaccine formulations (A-D represent different test article formulations).
Cytokine levels induced by the various mRNA-LNP formulations were assessed from blood serum taken on day 3 (group D) and day 1 (group A-C) following vaccine administration and analysed via meso-scale discovery (MSD) assay. Data is shown as mean ± SEM.
Results following neutralizing antibody detection assay for SARS-CoV-2 using the cPass detection kit.
Mice were injected with test article or negative control. Figure shows neutralizing antibody concentrations to SARS-CoV-2.
Representative image of vaccine biodistribution study
Following delivery of novel drug delivery vehicles for vaccine testing, the BLI signal allows to discriminate the distribution between the liver and spleen, providing real-time biodistribution and delivery information of novel therapeutic agents over time.
Available Vaccine Testing Readouts and Studies
The People Behind Your Research
Céline Erens, PhD, Immunology Study Director
An expert team led by our immunology study director; Céline Erens works together with you to help you set up optimal study designs. Curating the preclinical testing of your lead compounds with a deep understanding of the field is your solution to accelerating your drug development.
Yanick Fanton, PhD, Chief Scientific Officer
As Chief Science Officer at InnoSer, Yanick is responsible for all customer studies at InnoSer and takes care of the scientific and technical coordination.
Discover Other Related Oncology Research Models
Stay Curious: More Articles to Explore
Multiplex Cytokine and Immune Cell Profiling in Immuno-Oncology Research
The Meso-Scale Discovery (MSD) platform is a high-sensitivity, multiplex cytokine profiling analysis system, enabling you to simultaneously quantify multiple target cytokines, chemokines, antibodies, and growth factors from minute sample volumes (as low as 1 µL). By...
Pancreatic Cancer PDX Models
Last month, November, represented Pancreatic Cancer Awareness Month; a time to focus on the challenges posed by one of the most aggressive and lethal cancer types. Pancreatic cancer accounts for approximately 3% of all diagnosed cancers in Europe, with pancreatic...
Exploring InnoSer’s Key In vitro Oncology Services: PD-1 PD-L1 Blockade Assay
Immune Checkpoint Blockade in Oncology Drug Discovery In recent years, immune checkpoint blockade has emerged as a groundbreaking therapeutic strategy in immuno-oncology. Programmed cell death 1 receptor (PD-1), and its ligand programmed cell death ligand 1 (PD-L1)...
RENCA Mouse Mouse Model of Renal Cancer
Approximately 400,000 people are diagnosed with kidney cancer annually. Kidney tumors are classified into different subtypes based on the cell of origin. Over 85% of malignant renal cell tumors are RCC, with the other 15% being nephroblastic, mesenchymal and...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com